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Marfan syndrome (MFS) is an autosomal dominantly inherited connective tissue disorder, mostly caused by mutations in the
fibrillin-1 (FBN1) gene. We, by using targeted next-generation sequence analysis, identified a novel intronic FBN1 mutation (the
c.2678-15C>A variant) in aMFS patient with aortic dilatation.The computational predictions showed that the heterozygous c.2678-
15C>A intronic variant might influence the splicing process by differentially affecting canonical versus cryptic splice site utilization
within intron 22 of the FBN1 gene. RT-PCR and Western blot analyses, using FBN1 minigenes transfected into HeLa and COS-7
cells, revealed that the c.2678-15C>A variant disrupts normal splicing of intron 22 leading to aberrant 13-nt intron 22 inclusion,
frameshift, and premature termination codon. Collectively, the results strongly suggest that the c.2678-15C>A variant could lead to
haploinsufficiency of the FBN1 functional protein and structural connective tissue fragility in MFS complicated by aorta dilation,
a finding that further expands on the genetic basis of aortic pathology.
1. Introduction
Aberrant pre-mRNA splicing is a frequent cause of human
genetic disease and, according to some estimates, mutations
affecting splicing comprise up to 60% of all disease-causing
mutations in human genes [1, 2]. Molecular diagnostics, par-
ticularly with implementation of next-generation sequencing
(NGS) platforms, continues to identify new causative muta-
tions for rare genetic disorders such as Marfan syndrome
(MFS) that is often crucial for appropriate patient manage-
ment as well as for genetic risk assessment in families.
MFS is a heritable connective tissue disorder with clin-
ical pathological manifestations in the skeletal, ocular, car-
diovascular, and other systems [3]. In MFS, the develop-
ment of structural cardiovascular alterations such as aortic
aneurysms, mitral valve prolapse, dilated cardiomyopathy,
and arrhythmia greatly contributes to patient morbidity and
early mortality [4]. In situations of clinical uncertainty or
presymptomatic counseling [5], molecular genetic testing
and outcome predictions are an integral part of the diagnostic
decision process [6–8].
MFS is often associated with and caused by numerous
mutations (1847 currently reported, www.umd.be/FBN1/) in
the fibrillin-1 (FBN1) gene [9, 10]. A fast-track FBN1mutation
screening has therefore become a logical approach to add
meaning to the clinical MFS diagnosis, recognition of at-risk
cardiovascularMFS patients, and family planning counseling
[11]. In fact, diagnostic screening identified a wide spectrum
of pathogenic FBN1 mutations in MFS, resulting in FBN1
haploinsufficiency [8, 12]. However, for a substantial propor-
tion of patients withMFS clinical phenotypes, DNA sequenc-
ing restricted to FBN1 exons failed to identify putatively
pathogenic mutations. In some of these situations, qualitative
analysis of the FBN1 mRNA in dermal fibroblasts from MFS
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Table 1: Primers used in this study.
Primer Target F/R Application Sequence (5󸀠-3󸀠) PCR product
516 FBN1 e22 F PCR cloning (Not I) GTC TGC GGC CGC GAC CAT CAA GGG CAC TTG CTG GC 516-519: 2798 bp
519 FBN1 e24 R PCR cloning (EcoRV) CAG CGA TAT CAC AAG ACA GAT CCT TCC TGT GGC ATC
523 FBN1 i22 F Sequencing GTG AAT GCT GGA GGC CAT GAG AT
524 FBN1 i23 F Sequencing CTT CAC AGG GAG AAA TAT GCA GCA GA
525 FBN1 i23 F Sequencing CTC CAT TAG GCA AAC TGG GAA GGA
480 Vector 5󸀠UTR F Sequencing GCA GAG CTC GTT TAG TGA ACC GTC
481 Vector 3󸀠UTR R Sequencing GCA ACT TCC AGG GCC AGG AG
521 FBN1 e22 F RT-PCR ACC ATC AAG GGC ACT TGC TGG C
530 Vector c-Myc R RT-PCR CCT CAC AGA TCC TCT TCT GAG ATG AGT 521-530: 374 bp
36 RPL19 e2-3 F RT-PCR AAC TCC CGT CAG CAG ATC CG
65 RPL19 e6 R RT-PCR CTT GGT CTC TTC CTC CTT GGA 36-65: 480 bp
528 Vector FLAG F RT-PCR ATG GAC TAC AAA GAC CAT GAC GGT GA
533 FBN1 e23-22 R RT-PCR CCA CAT ATG GGA TCA ACT TGG CAT AG 528-533: 230 bp
535 FBN1 e23-i22 R RT-PCR CCT TTA CCA CAT ATG GGA TCT GTA ATA AAA AG 528-535: 250 bp
patients revealed aberrant FBN1 pseudoexon inclusions due
to intronic mutations which activate cryptic splice sites [13–
17].
We describe a patient with a diagnosis of MFS where
there is no mutation identified in the FBN1 coding sequence.
TargetedNGS of the genomicDNA from this patient revealed
a novel variant located in intron 22 of the FBN1 gene. The
results of both in silico and functional studies usingminigene
splicing assays strongly suggest that this variant leads to a
cryptic acceptor splice site activation and subsequent frame
shift and premature termination codon (PTC) in exon 23.
2. Materials and Methods
2.1. Patient Information. The index patient was a 32-year-old
male with MFS. Clinical findings included aortic root dilata-
tion (41 mm aortic sinus, 44 mm or 2.17cm/m2 ascending
aorta), ectopia lentis, and typical skeletal manifestations. His
father had aortic dilatation and died in his forties due to
endocarditis after the implantation of an aortic prosthesis.His
mother, his brother, and one paternal aunt were clinically
unaffected. Since no relevant mutation was identified in a
previous genetic study limited to exons and close flanking
intronic regions of the FBN1 gene, the patient requested
a new evaluation as he and his couple were considering
the possibility of in vitro fertilization with preimplantation
genetic diagnosis.Three nonaffected patient’s relatives as well
as 4752 individuals with phenotypes other than MFS
were also genetically tested. Written informed consent was
obtained from all subjects before the study. The project was
approved by each local ethics committee.
2.2. Genomic DNA Extraction. The patient’s and relative’s
genomic DNA was extracted from saliva samples collected
with the DNA Sample Collection Kit OG-500 (Oragene), on
the QIAsymphony SP robot using the QIAsymphony DNA
midi Kit (Qiagen). Purified genomic DNA was quantified
using Nanodrop 1000 Spectrophotometer (Thermo Scien-
tific) and DNA integrity was determined on the 2200 TapeS-
tation (Agilent Technologies) following the manufacturer’s
recommendation.
2.3. Next-Generation Sequencing. Custom probe RNA baits
(120 nucleotides) for NGS were designed using Agilent’s
SureDesign online tool to cover all exons and exon/intron
boundaries of the human FBN1 gene. In addition, another
34 genes included in the Health in Code panel (see the
Genetic Testing Registry at NCBI, Test ID: GTR000530671.1,
www.ncbi.nlm.nih.gov/gtr/tests/530671) related to aortic
diseases and phenocopies were NGS analyzed. For NGS
library construction, patient genomic DNA (3 𝜇g) was
sheared into 150-200 bp fragments by Covaris E220 fo-
cused-ultrasonicator. Preparation and capture of NGS
libraries were performed on the Bravo instrument (Ag-
ilent Technologies) following the manufacturer’s instruc-
tions. The DNA libraries were normalized to 10 nM and then
pooled for multiplexed sequencing (HiSeq 1500, Illumina).
Filtering of variants was performed using in-house data
sets, the database of single-nucleotide polymorphisms
(www.ncbi.nlm.nih.gov/projects/SNP/, build 132), Human
Gene Mutation Database (HGMD, http://www.hgmd.cf.ac
.uk/ac/index.php), and the Health in Code database. In order
to confirm the FBN1 variants identified by NGS, a standard
PCR amplification and bidirectional Sanger sequencing
were performed. In silico analysis of identified variants
was performed using the splicing prediction module of the
Alamut Visual v.2.9.0 software (Interactive Biosoftware),
running five independent algorithms for splice signal
detection: SpliceSiteFinder-like (SSF), MaxEntScan (MES),
NNSPLICE (NNS), GeneSplicer (GSP), and Human Splicing
Finder (HSF).
2.4. Generation of Allelic Minigene Constructs. FBN1 allelic
minigene fragments (2798 bp), including either the reference
(Ref) or mutated (Mut) sequence, have been generated by
PCR using the patient genomic DNA as template, Phusion
Hot Start II high-fidelity DNA polymerase (Thermo Scien-
tific), and primers 516-519 (Table 1). The agarose-gel purified
PCR fragments were cloned into a linearized dual tagged
(N-terminal 3xFLAG and C-terminal c-Myc) expression
vector (p3xFLAG-Myc-CMV-26, Sigma) as detailed in Supp.
Figure 1A. Plasmids grown in XL1-Blue Supercompetent E.
coli cells (Stratagene) were purified by using a PureLink
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Figure 1: Schematic representation of in silico analysis of the c.2678-15C>A variant identified in intron 22 of the FBN1 gene by various
computational tools. (a) Representation of the position of the canonical (c.2678, black triangle) and cryptic (c.2678-13, grey triangle) splice
site identified in the reference (RS) andmutated sequence (MS), respectively. Arrow: the C to A pointmutation (c.2678-15C>A).The intron 22
(i22) sequence is shown in lower case and exon 23 (E23) sequence in upper case. (b)The predicted splice score of the canonical site decreases
by 29.8% and 49.7% in the mutated sequence (grey parallelogram) versus the reference sequence (black parallelogram) as revealed by the
MES and GSP algorithm, respectively. (c) The predicted splice scores of a new cryptic splice site due to the c.2678-15C>A mutation.
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HiPure plasmid filter purification kit (Invitrogen) according
to the manufacturer’s protocol. All the FBN1 constructs were
verified by full-length insert sequencing (for primers, see
Table 1). Plasmid 1283 was selected as the FBN1-Refminigene,
and plasmid 1288 was selected as the FBN1-Mut minigene
(Supp. Figure 1B). Plasmids were formulated at a final DNA
concentration of 1 mg/ml in sterile isotonic saline.
2.5. Cell Culture and Transfection In Vitro. HeLa (an epithe-
lial cell line derived from human cervical epithelioid car-
cinoma, passage +4) and COS-7 (a fibroblast-like cell line
derived from African green monkey kidney tissue, passage
+5)were purchased from the EuropeanCollection ofAuthen-
ticated Cell Cultures (Sigma). Cells were trypsinized at
70–80% confluence, cell numbers were determined using an
automated cell counter (Countess, Invitrogen), and 100,000
HeLa or 60,000 COS-7 cells/well were plated in 12-well
culture plates, allowed to attach overnight, and transiently
transfected with 1.0 𝜇g of plasmid DNA. All transfections
were carried out with Lipofectamine 3000 (Invitrogen) fol-
lowing the manufacturer’s instructions. For each plasmid,
four separate transfection assays were employed, and in
each assay transfections were performed in duplicate. The
transfection efficiency, evaluated by cotransfection with a
CMV-EGFP (enhanced green fluorescent protein) vector
followed by fluorescent microscopy, was 70-80%. Equivalent
transfection efficiency was verified by cotransfection with a
plasmid coding for the N-terminal 3xFLAG-tagged bacterial
alkaline phosphatase (BAP) fusion protein (p3XFLAG-CMV-
7-BAP, Sigma) followed by Western blot detection with an
anti-FLAG antibody. Additional controls included mock and
empty vector-transfected cells. In some experiments, the
transfected cells were incubated with the cell-permeable
proteasome inhibitor MG132 (Sigma) or dimethyl sulfoxide
(Sigma) vehicle for 7 hours.The cells were harvested at 24–48
hours after transfection and processed for RNA and protein
extraction.
2.6. Semiquantitative RT-PCR. Total RNA was extracted by
RNeasy-Mini Kit (Qiagen) according to the manufacturer’s
protocol, subjected to column digestion of DNAwith RNase-
free DNase (Qiagen), and reverse transcribed using Super-
Script IV (Invitrogen) and oligo-dT primers. Semiquan-
titative RT-PCR was performed in a Biometra II system
using the RPL19 gene (coding for ribosomal L19 protein) for
normalization of RT-PCR data [18]. The amount of cDNA
and the number of cycles were varied for each primer pair
(see Table 1) to ensure amplification within the linear phase.
Reactions, including non-RT control and nontemplate con-
trol, were performed at least in triplicate. PCR products were
visualized on 2% agarose gels by ethidium bromide staining
and band intensity was estimated by densitometry (VersaDoc
1000) and Quantity One software (Bio-Rad).
2.7. SDS-PAGE and Western Blotting. Cell samples were
homogenized and solubilized in standard 2X Laemmli buffer
(Invitrogen) supplemented with complete protease inhibitor
cocktail (Roche). Following centrifugation at 20,000 g for
30 minutes, the concentration of supernatant proteins was
analyzed using the Bio-Rad DC Protein Assay Kit accord-
ing to the manufacturer’s protocol. Extracted proteins were
subjected to SDS-PAGE (Mini-Protean-III, Bio-Rad), stained
with Coomassie or blotted onto PVDFmembranes (Hybond-
P, Amersham Bioscience), and probed with mouse mono-
clonal anti-Myc or anti-FLAG antibodies (Sigma). Molecular
weight (MW) standards (MARK-12 and SeeBlue Plus2 from
Invitrogen) were included on each gel. Equivalence of protein
loading was confirmed by Amido Black staining of blots
after immunodetection. Blocking, washing, incubation with
diluted primary and secondary HRP-conjugated antibodies
(Sigma), and visualization of immunodecorated bands by the
Super-Signal West Pico PLUS chemiluminescent substrate
(Thermo Scientific) were carried out as previously described
[19].
3. Results
DNA from patient saliva was used for FBN1 gene targeted
NGS analysis with in-house analysis pipeline. Paired end
sequencing covered nearly 34,000 bases of FBN1 encom-
passing 66 exons along with their flanking (200 bp) intron
regions. A total of 8 variants of FBN1were identifiedwith high
variant-calling stringency including 7 variants localized in
intronic noncoding regions and one synonymous exonic vari-
ant which does not influence the amino acid structure of the
protein (Table 2). All variants were confirmed by Sanger
sequencing. It is worth noting that the identified variants,
with the exception of the heterozygous c.2678-15C>A, have
been previously described in the database of short genetic
variation (dbSNP) and classified as benign or uncertain in the
ClinVar database. NGS coverage analysis metrics across the
region of interest for FBN1 allowed for the identification of
the heterozygous c.2678-15C>A variant which are shown in
Supp. Figure S2.The c.2678-15C>A variant was not identified
by Sanger sequencing in any of the three clinically unaffected
patient’s relatives. This variant was also not detected in
the control population consisting of 4752 individuals with
phenotypes other than MFS who were referred to the Health
in Code laboratory for NGS analysis. In addition, our NGS
screening of a panel of 34 genes related to aortic diseases or
involved in the differential diagnosis of MFS did not reveal
any pathogenic variant in the case patient.
To verify the potential role of FBN1 variants identified
by NGS screening, we used the Alamut Visual predictive
software. The computational predictions showed that only
the heterozygous c.2678-15C>A intronic variant might influ-
ence the splicing process by differentially affecting canonical
versus cryptic slice site utilization (Figure 1). Relative to the
canonical acceptor site c.2678 of the human FBN1, MES and
GSP programs, respectively, showed a score reduction of
approximately 30% and 50% for the c.2678-15C>A intronic
variant as compared to reference sequence, while the score
values calculated by the remaining three programs (SSF,NNS,
and HSF) were estimated to be unaltered (Figure 1(b)). As
concerns the cryptic splice site c.2678-13, in contrast, all
five Alamut algorithms predicted with high probability (see
Figure 1(c)) that the c.2678-15C>A intronic variant would
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Figure 2: RT-PCR analysis ofminigene-derived transcripts. (a) Schematic representation of FLAG (F) andMyc- (M-) tagged reference (FBN1-
Ref) and mutant (FBN1-Mut) minigene plasmids (PL). Exons (E) are denoted with white boxes and introns (i) with solid black horizontal
lines. The approximate location of the primers for downstream RT-PCR analysis is shown (for primer sequences see Table 1). (b) Expression
of FBN1-Ref and FBN1-Mutminigenes inHeLa and COS-7 cells as revealed by RT-PCR, using primers (521 and 530) targeting E22 andMyc. A
representative of two independent experiments for each transfection is shown. RPL19 amplification was carried out as an input RNA control
for the RT-PCR. L: size reference ladder. MC: mock cells. (c) Schematic representation of PCR products corresponding either to correct
splicing (374 bp band) or to partial inclusion (dark grey box) of intron 22 (387 bp band) as revealed by sequencing (see Supp. Figure S3). (d)
Partial inclusion of intron 22 in transcripts was assayed by using different combinations of primers targeting FLAG (primer 528 shown in
(a)), exon 22/exon 23 junction (primer 533), or exon 23/retained intron 22 inside (primer 535). (e) A diagram of the PCR products (i.e., the
230 bp and 250 bp bands shown in (d)) as revealed by sequence analysis.
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Table 2: Identified FBN1 variants using targeted NGS.
FBN1 variant compared to RS: Location Zygosity SNP ID Frequency1 Splicing2
NC 000015.10 NM 000138.4
1 g.48610929A>G c.248-103T>C intron 3 HZ rs1018148 0,932343 NA
2 g.48537938C>G c.539-130G>C intron 6 HTZ rs147780575 NR NA
3 g.48494269G>T c.2678-15C>A intron 22 HTZ NR NR A4
4 g.48488453G>A c.3123C>T5 exon 26 HTZ rs576395584 0.00001 NA
5 g.48444487A>T c.6037+54T>A intron 49 HZ rs2303502 0.22331 NA
6 g.48437451T>C c.6314-64A>G intron 51 HZ rs2042746 0.39285 NA
7 g.48428329G>C c.6997+17C>G intron 57 HZ rs363832 0.27742 NA
8 g.48421799G>T c.7571-113C>A intron 61 HZ rs1820488 0,813073 NA
RS: reference sequence; g.: genomic; c.: coding DNA; HZ: homozygous; HTZ: heterozygous; NR: not registered; NA: not affected; A: affected.
1Population frequency from gnomAD (Genome Aggregation Database) except 3from dbSNP.
2Alamut Visual v.2.9 predictions.
4Activation of a cryptic acceptor splice site at c.2678-13 (see Figure 3).
5NP 000129.3:p.(His1041=).
activate a cryptic acceptor splice site within intron 22, at
position 13 nucleotides (nt) prior to exon 23.
Taken together, these results strongly suggested that the
c.2678-15C>A intronic variant induces a cryptic splice site
in intron 22 of the FBN1 gene that in turn could lead to an
inefficient recognition of canonical splice site, giving rise to a
frameshift and premature termination codon (PTC) in the
FBN1mRNA.
To investigate the effect of the FBN1 splice site variant
c.2678-15C>A at the RNA and protein level, we used a
minigene approach with reference (Ref) and mutant (Mut)
expression plasmids containing the FBN1 fragments which
were amplified from the patient genomic DNA (see Supp.
Figure S1). Each plasmidwas transfected intoHeLa andCOS-
7 cells for transient expression. RT-PCR amplifications of
the mini-Ref transcript with different primer sets yielded
single bands of the expected size (Figure 2(b); 374 bp bands)
corresponding to the normal inclusion of exons 22, 23,
and 24, with introns 22 and 23 having been removed. The
sequencing of these RT-PCR products confirmed that the
introns were removed and the exons were correctly ligated
together (Figure 2(c) and Supp. Figure S3A). In contrast,
slightly longer 387 bp bands were PCR amplified from HeLa
and COS-7 cells transfected with the mini-Mut plasmid (see
Figure 2(b)). These RT-PCR products were eluted from the
gel and sequenced.The 387 bpmini-Mut band included exon
22, a part (13 nt) of intron 22, and exons 23 and 24 (see Fig-
ure 2(c) and Supp. Figure S3B). The results indicated that the
FBN1 c.2678-15C>A variant affects splicing by promoting the
insertion of a 13-nt intron 22-derived sequence in the FBN1
transcript due to activation of a cryptic splice site localized
at c. 2678-13. A more detailed PCR analysis using primers
located inside the intron 22-derived insertion (Figure 2(c))
revealed that the aberrantly spliced transcript was expressed
in HeLa and COS-7 cells transfected with the mini-Mut
plasmid being not detected in cell transfectants expressing
mini-Ref plasmids (Figures 2(d) and 2(e)).The latter supports
the suggestion that the FBN1 c.2678-15C>Avariant could lead
to haploinsufficiency of full-length FBN1 protein.
Overall, the data demonstrated that the c.2678-15C>A
variant can repress recognition of the canonical splice site in
intron 22 of the FBN1 gene causing a shift from canonical
toward cryptic splicing that can lead to insertion of a 13-nt
intron 22-derived sequence, frameshift, and the creation of
a PTC (see Supp. Figure 3B). Following the standards and
guidelines for the interpretation of sequence variants [20],
theFBN1 c.2678-15C>Amutationwas classified as pathogenic
(see Supp. Table S1) and submitted to the ClinVar database
at NCBI (www.ncbi.nlm.nih.gov/clinvar/) with the accession
number SCV000611711.
The relative level of transcripts produced in themini-Ref-
containing cells was comparable with that observed in cells
transfected with the mini-Mut construct (see Figure 2(b)),
suggesting that the aberrantly spliced transcripts may escape,
at least partly, from a nonsense-mediated mRNA decay
(NMD) under our experimental conditions.
To verify whether these aberrantly spliced transcripts are
translated into protein products, we performed SDS-PAGE
and Western blotting of protein lysates of HeLa and COS-7
cells transfected with FLAG/Myc-tagged mini-Ref and mini-
Mut plasmids. The 18 kDa bands were detected by both anti-
FLAG and anti-Myc antibodies in HeLa (Figure 3(a)) and
COS-7 (Figure 3(b)) cells expressing the mini-Ref plasmid
1283.Their apparent molecular weight (MW) values (18 kDa)
were found to acceptably match the deduced MW sum of the
mini-Ref FBN1 sequence, three FLAG and one c-Myc tags
(i.e., 16.6 kDa, see Figure 4(b)). Surprisingly, neither the 18-
kDa band nor any others were detectable in cells transfected
with the mini-Mut plasmid 1288 (see Figure 3) although
these cell transfectants produced high levels of the aberrantly
spliced transcript (see Figure 2).
It is widely accepted that aberrant proteins can be rapidly
degraded by the ubiquitin proteasome system (UPS). To
determine whether inhibition of the UPS may influence the
detection of proteins from the aberrantly spliced transcripts,
we performed an analysis of proteasome inhibitor MG132
treatment of HeLa cells transfected with mini-Ref and mini-
Mut constructs containing three FBN1 exons with flanking
introns. Western blot revealed that MG132 treatment rescues
protein expression of themini-Mut construct in, respectively,
transfected cells to levels comparable to those observed in
the cells transfected with the mini-Ref plasmid; this rescue
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Figure 3:Western blot analysis ofminigene-derived proteins. (a) FLAG/Myc-tagged reference (FBN1-Ref) andmutant (FBN1-Mut)minigene
plasmids (PL) were transfected into HeLa cells as indicated at the top of each lane, and cell lysates were analyzed by Western blotting with a
mouse monoclonal anti-FLAG (upper panel) or anti-Myc (lower panel) antibody. The results from experiments performed on four batches
of cells for each transfection are shown. Lane 13: cells transfected with empty vector.TheWestern blot detection of the FLAG-tagged bacterial
alkaline phosphatase (BAP) was used as a marker of equivalent transfection efficiency and equal loading. MW values (kDa) of the bands
detected are shown in brackets. (b) COS-7 cells were transfected as indicated at the top of each lane and analyzed by Western blotting
with a mouse monoclonal anti-FLAG antibody (upper panel). Protein load (lower panel): membrane stained with Amido Black 10B after
immunostaining. Other indications as in (a).
effect was dose-dependent (Figure 4). As might be expected
in the presence of a PTC in the aberrant transcript (see Supp.
Figure S3B), the corresponding protein band was of a lower
MW in comparisonwith that of the correctly processedmini-
Ref construct, i.e., 9 kDa versus 18 kDa, respectively (see
Figure 4(a)). Notably, these apparent MW values estimated
by SDS-PAGE andWestern blotting were very similar to their
respective deduced MW values (see Figure 4(b)). Anti-
Myc detection did not reveal the expression of the 9 kDa
alternative protein in the mutant transfected cells (data not
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Figure 4: Treatment of transfected cells with MG132 leads to detection of truncated proteins derived from mutant FBN1 constructs. (a)
FLAG/Myc-tagged reference (FBN1-Ref; PL 1283) and mutant (FBN1-Mut; PL 1288) minigene plasmids (PL) were transfected into HeLa
cells as indicated at the top of each lane. Lane 9: mock cells. Either the proteasome inhibitor MG132 or the DMSO vehicle was applied to
transfected cells as indicated in Materials and Methods. Whole-cell extracts of transfected cells were analyzed by Western blotting with a
mouse monoclonal anti-FLAG antibody. Black arrows: MW values (kDa) of the bands detected. (b) A diagram of the protein products as
predicted by sequence analysis of the corresponding cDNAs. Deduced MW values (kDa) are also indicated. Dark grey box: partial inclusion
of intron 22; F: FLAG epitope; M: Myc epitope; PTC: premature termination codon.
shown) because the FBN1 c.2678-15C>A variant produced, as
predicted, a frame shift and PTC within exon 23. Because of
the PTC, the Myc-coding region will not be read-through.
4. Discussion
Our study adds to the mutational spectrum of the FBN1 gene
inMFS. Using a previously unrecognized variant in intron 22
of the FBN1 gene (c.2678-15C>A), revealed by targeted NGS
in aMFS patient, we demonstrate, as a proof-of-concept, that
this variant causes aberrant splicing, frameshift, and PTC.
This pathogenic variant induces aberrant FBN1 pre-mRNA
splicing by the generation of a new cryptic acceptor site that
outcompetes the canonical splice site.The single nucleotide C
to A change in intron 22 of the FBN1 is, therefore, considered
clinically relevant to MFS. In contrast, the known C to T
nucleotide substitution at the same site (i.e., c.2678-15C>T,
rs181681840) is not expected to have any clinical significance
because its population frequency (1% in the African pop-
ulation; gnomad.broadinstitute.org/variant/15-48786466-G-
A) is not consistent with MFS incidence data (approximately
1 case per 5000 individuals [14]), and multiple lines of
computational evidence suggest no impact on gene product;
the variant c.2678-15C>T is classified as benign in ClinVar
(www.ncbi.nlm.nih.gov/clinvar/variation/137303).
Pointmutation variants that affect FBN1 pre-mRNAsplic-
ing represent approximately 10% of reported FBN1mutations
in patients with MFS [12] and are frequently associated with
aortic wall alterations [13]. The accumulated data clearly
indicate that splice mutations located besides the FBN1 exon-
coding area and canonical exon’s splice sitemotifs also play an
important role in MFS [21]. In particular, it was found that
patients suffering fromMFS can carry FBN1 intronic variants
resulting in cryptic splicing and exonization of intronic
sequences at the transcript level [13–16, 22].
In this work, we identified a new intronic variant (c.2678-
15C>A) of the FBN1 gene in a patient with a classic MFS
phenotype.Themutation was not identified in his unaffected
mother, brother, and paternal aunt and could have been
inherited from his deceased father who was retrospectively
considered as very likely affected by MFS.
We showed, using minigene functional assays followed
by sequencing, that this variant leads to the exonization
(insertion) of a part of the intron 22 sequence into FBN1
transcripts by aberrant splicing. The insertion leads to
frameshift and creates a PTC in exon 23 (see Supp. Figure
BioMed Research International 9
S3). Mechanistically viewed, this PTC would unlikely be
expected to direct the corresponding transcript(s) to NMD,
because it is located in a NMD-insensitive region, less than
50 nt upstream of the 3󸀠-most exon-exon junction measured
after splicing [23]. Our data strongly suggest that aberrantly
spliced transcripts carrying this PTC, located 38 nt upstream
of the junction between exons 23 and 24 in the spliced mini-
gene (Supp. Figure S3B), could escape NMD in transfected
cells and express unstable truncated proteins which were only
detectable upon proteasome inhibition with MG132.
Although as yet unproved, we believe that the c.2678-
15C>A variant would lead to haploinsufficiency of the FBN1
functional protein and structural connective tissue fragility.
Our NGS analysis did not reveal any relevant change in a
panel of 34 additional genes related to aortic diseases or
involved in the differential diagnosis of MFS, supporting the
assumption that the c.2678-15C>A variant of the FBN1 can
be considered as a main disease-causing variant in the case
patient.
5. Conclusion
The intronic c.2678-15C>A substitution has not previously
been reported, representing therefore a novel FBN1 gene
variant in MFS. Our results demonstrate that the identified
intronic variant disrupting normal FBN1mRNA splicing is a
MFS-associated mutation that should be taken into account
in the diagnosis of patients with MFS. On the basis of our
results, we suggest that the clinical phenotype associated with
the intronic c.2678-15C>A variant is caused by a reduction
of wild-type FBN1 protein. Our findings and others highlight
the potential importance of intronic FBN1 variants in causing
MFS as well as the continued need for identifying noncoding
mutations in the FBN1 gene.
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